Showing results (31-40 of 324) with videos related to
Sort By:
Pageof 33
Journal of Immunology (Baltimore, Md. : 1950)|January 24, 2007
Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responsesYanyan Lou, Chengwen Liu, Grace J Kim, et al.Clinical Genitourinary Cancer|February 14, 2009
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenibZita Dubauskas, Joy Kunishige, Victor G Prieto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2018
T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid TumorsJiemiao Hu, Chuang Sun, Chantale Bernatchez, et al.RMD Open|August 30, 2024
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case seriesYuanteng Jeff Li, Pavlos Msaouel, Matthew Campbell, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 4, 2014
Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical developmentGeok Choo Sim, Jessica Chacon, Cara Haymaker, et al.Nature Clinical Practice. Oncology|October 22, 2008
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenibAlfonso Quintás-Cardama, Alexander J Lazar, Scott E Woodman, et al.International Immunology|September 28, 2007
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cellsShujuan Liu, Gregory Lizée, Yanyan Lou, et al.Cancer Immunology, Immunotherapy : CII|December 29, 2010
A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403-455)Yufeng Li, Clay L Efferson, Rajagopal Ramesh, et al.Gynecologic Oncology|October 28, 2018
Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trialsEmily Hinchcliff, David Hong, Hung Le, et al.Journal for Immunotherapy of Cancer|December 14, 2020
Strategies for improving the management of immune-related adverse eventsAung Naing, Joud Hajjar, James L Gulley, et al.Pageof 33